[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"amphetamine-use-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:amphetamine-use-disorder":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100649445","applying-low-intensity-focused-ultrasound-in-treating-severe-substance-use-disorder-tolerability-and-effectiveness-100649445",false,"NCT07734623","Applying Low-Intensity Focused Ultrasound in Treating Severe Substance Use Disorder: Tolerability and Effectiveness","Inclusion Criteria:\n\n* Meets the DSM-5 criteria for opioid use disorder or amphetamine use disorder, with a severity level of severe, and does not currently meet the criteria for in sustained remission;\n* Within 7 days prior to the screening assessment, the participant must have been receiving a stable dose of medication treatment, such as methadone, buprenorphine\u002Fnaloxone, or naltrexone;\n* Within 7 days prior to the screening assessment, the participant must have abstained from illicit substances and alcohol, and must have a negative urine drug test;\n* The bilateral nucleus accumbens must be clearly identifiable on magnetic resonance imaging (MRI), such that they are sufficient for treatment targeting and for indirect measurement from other anatomical structures;\n* The participant must be able to communicate effectively and express their feelings and experiences during the study procedures;\n* The participant must be willing to comply with the study requirements, including adherence to prescribed medications and cooperation with study visits and assessments.\n\n(The participant must have the capacity to make independent medical decisions, as determined by the clinical team.)\n\nExclusion Criteria:\n\n* Presence of neurological disorders or major psychiatric disorders, such as acute-phase schizophrenia spectrum disorder, acute-phase bipolar disorder, acute-phase major depressive disorder, severe cognitive impairment, or recent suicidal ideation or plan;\n* Antisocial personality disorder;\n* Occurrence of major physical health problems within 6 months prior to the trial, including: Cardiovascular or hemodynamic abnormalities, such as heart failure, arrhythmia, tachycardia or bradycardia (\\>100 bpm or \\\u003C60 bpm), abnormal systolic blood pressure (\\>180 mmHg or \\\u003C90 mmHg), or abnormal diastolic blood pressure (\\>180 mmHg); Platelet or coagulation abnormalities (INR \\> 1.5) or current use of medications that may cause anticoagulation, such as warfarin or Avastin; Renal dysfunction (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²) or ongoing hemodialysis; Severe infection; Immunocompromised status; History of intracranial hemorrhage, intracranial aneurysm, cerebrovascular events within the past 6 months, or brain tumor; Neurological diseases, such as stroke, epilepsy, Parkinson's disease, dementia, or related disorders; Any other physical illness that, based on clinical evaluation, may pose a significant risk to physical function or life during treatment.\n* Participants who, upon evaluation, are deemed unsuitable for MR-guided focused ultrasound treatment, including those with a low skull density ratio (\\\u003C0.4), intracranial implants, or energy-absorbing structures or sensitive tissues along the ultrasound beam path that cannot be avoided (such as prior ventriculoperitoneal shunt sites, surgical metal clips, significant calcifications, extensive scarring, or any rigid implants). During the pre-treatment evaluation, a head CT scan will be performed to determine whether the skull density ratio is suitable for focused ultrasound treatment. Based on prior theoretical evidence, an excessively low skull density ratio may reduce the efficiency of MR-guided focused ultrasound and increase the risk of adverse effects, and therefore such participants are considered unsuitable for focused ultrasound treatment.\n* Structural abnormality of either side of the nucleus accumbens;\n* Contraindications to MRI, such as claustrophobia, allergy to MRI contrast agents, or the presence of metallic implants incompatible with MRI;\n* Contraindications to PET imaging, such as allergy to radiopharmaceutical contrast agents;\n* Inability to comply with trial-related instructions, lack of legal\u002Fbehavioral capacity, or lack of motivation to receive treatment;\n* Pregnancy or breastfeeding;\n* Scalp atrophy or poor wound healing of the scalp;\n* Any other condition that, in the physician's judgment, makes the participant unsuitable for enrollment in the clinical trial.","ALL","20 Years","50 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to investigate the safety and efficacy of applying low-intensity focused ultrasound targeting the nucleus accumbens in individuals with opioid or amphetamine use disorders. The main questions it aims to answer is:\n\n\\- Low-intensity focused ultrasound targeting the nucleus accumbens demonstrates sufficient safety and predictable therapeutic efficacy in individuals with opioid or amphetamine use disorders.\n\nParticipants will:\n\n* Received Low-intensity focused ultrasound neuromodulation once\n* Visit the clinic for checkups and asessment at 1 week, 1 month, 3 months, 6 months, 9 months, 1 year, 1.5 years, and 2 years after received Low-intensity focused ultrasound neuromodulation.",[26,27],"Opioid Use Disorder, Severe","Amphetamine Use Disorder","RECRUITING","2026-07-30",{"date":31,"type":32},"2026-07-31","ACTUAL",{"date":34,"type":32},"2025-01-01",{"date":36,"type":20},"2030-12-31",{"name":38,"class":39},"National Taiwan University Hospital","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":51,"conditions":52,"keywords":59,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":40},"100589888","effects-of-repetitive-transcranial-magnetic-stimulations-in-patients-with-amphetamine-use-disorders-100589888","NCT06960265","Effects of Repetitive Transcranial Magnetic Stimulations in Patients With Amphetamine Use Disorders","A Pilot Study for the Effects of Repetitive Transcranial Magnetic Stimulation in Patients With Amphetamine Use Disorders: Clinical Outcomes, Near InfraRed Spectroscopy, and Biomarkers","Inclusion Criteria:\n\n* Age ≥20 years.\n* Meeting DSM-5 criteria for substance use disorder made by a specialist in addiction psychiatry.\n* Fluency in Chinese.\n* Willingness and ability to comply with study requirements.\n* Good physical health determined by complete physical examination, and laboratory tests.\n* Patient or a reliable caregiver can be expected to ensure acceptable compliance and visit attendance for the duration of the study.\n* Trained psychiatrists will assess eligible patients using the structured clinical interview for the Mini-International Neuropsychiatric Interview (MINI) (Sheehan et al., 1998) to determine the presence of any psychotic disorder.\n\nExclusion Criteria:\n\n* Evidence of an uncontrolled and\u002For clinically significant medical condition, e.g., cardiac, hepatic and renal failure that would compromise patient safety or preclude study participation.\n* Premorbid mental retardation.\n* Other major Axis-I Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) diagnoses other than substance use disorder.\n* Pregnancy or nursing.\n* History of seizures or epilepsy.\n* History of neurological diseases or traumatic brain injury.\n* Suicidal attempts or risks during screening or study period.\n* Presence of prosthesis devices, e.g. pace-makers, cochlear prosthesis, neuro- stimulators, magnetic cochlear prosthesis, intraocular metallic fragments.",{"count":49,"type":20},20,[23],"Amphetamine Use Disorder (AUD) is a major public health issue in Taiwan, where it is the most commonly abused illegal drug. There are currently no effective approved medications to treat it, which makes finding new treatment options urgent. Repetitive Transcranial Magnetic Stimulation (rTMS), a non-invasive brain stimulation method, has shown promise in reducing cravings and drug use in people with addiction, but its effects on AUD are not well studied.\n\nTo explore this, the investigators plan to conduct a double-blind, sham-controlled study with 20 people diagnosed with AUD. Half will receive real rTMS treatment, and half will receive a placebo-like sham treatment. The treatment targets a specific brain area (the left dorsolateral prefrontal cortex) and will be given 10 times over two weeks.\n\nThe investigators will assess the effectiveness of rTMS by tracking drug cravings, urine test results, and side effects with follow-up over 12 weeks. The investigators also include brain imaging using near-infrared spectroscopy (NIRS) after the treatment.\n\nThe study aims to better understand how rTMS might help reduce amphetamine cravings and improve outcomes, potentially leading to new treatment options for AUD.",[53,27,54,55,56,57,58],"Amphetamine Use Disorders","Amphetamine Dependence","Amphetamine Abuse","NIRS","rTMS","rTMS Stimulation",[60,61,56],"amphetamine","rtms","NOT_YET_RECRUITING","2025-04-28",{"date":65,"type":32},"2025-05-07",{"date":67,"type":20},"2025-05-15",{"date":69,"type":20},"2025-12-31",{"name":71,"class":39},"TsaoTun Psychiatric Center, Department of Health, Taiwan",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":15,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":84,"phases":4,"briefSummary":85,"conditions":86,"keywords":93,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":40},"100569995","role-of-pavlovian-mechanisms-for-control-over-substance-use-100569995","NCT06701487","Role of Pavlovian Mechanisms for Control Over Substance Use","SFB TRR 265: Losing and Regaining Control Over Drug Intake Work Package 1 of Project B03: General and Specific Pavlovian-to-Instrumental Transfer Effects in a Range of Substance Use Disorders","ReCoDe","Inclusion Criteria:\n\n* Men and women between 18-65 years of age,\n* AUD, and\u002For SUD subjects only: meet 4 or more criteria for DSM-5 alcohol-related and\u002For substance-related (cannabis, amphetamine, methamphetamine or cocaine disorder (not requiring withdrawal as assessed by an independent psychiatrist),\n* Currently using alcohol without a desire for abstinence\n* Ability to consent to the study and complete the questionnaires.\n* Sufficient language(German) and motor skills for using PC\n* existing health insurance\n\nExclusion Criteria:\n\n* Lifetime diagnosis of DSM-5 bipolar disorder or schizophrenia or schizophrenia spectrum disorder (if induced by drugs, it should happen more than a month ago)\n* Current threshold DSM-5 diagnosis of major depressive disorder, or presence of suicidal intention\n* High risk (≤ 26) ASSIST scores in other substances other than alcohol, amphetamine, methamphetamine, cannabis, cocaine, tobacco\n* History of traumatic brain injury or severe neurological disease (such as Dementia, Parkinson's disease, multiple sclerosis, Epilepsy, Meningitis, Stroke)\n* Pregnancy or breastfeeding,\n* Ingestion of medications known to interact with the dopamine system in the 10-day period prior to study participation or less than 4 half-lives after last ingestion (rapid urine test); A detailed list of permitted medication can be added upon request\n* MR contraindications (e.g., pacemakers, metallic or electronic implants, metallic splinters, surgical staples)\n* Color vision deficiency\n* sensorineural hearing loss of 30 dB or greater,\n* Tinnitus and\n* Acute alcohol, substance (cannabis, or methamphetamine, amphetamine, cocaine) intoxication at assessement day verified by breath alcohol tests and drug intoxication verified by rapid urine test.","18 Years","65 Years",{"count":83,"type":20},200,"OBSERVATIONAL","During the first funding period (1st FP), the investigators developed a novel full Pavlovian-to-instrumental transfer (PIT) task that allows assessing both, general and specific PIT to investigate whether specific PIT differs between alcohol use disorder (AUD) and control subjects. Preliminary analyses of the full transfer task indicate that AUD participants exhibit a stronger specific PIT effect compared to controls. Based on these findings, the investigators want to compare specific and general PIT effects in patients with moderate to severe substance use disorders (alcohol, cannabis, methamphetamine, amphetamine and cocaine) to healthy controls on the behavioral and neural level (fMRI).",[87,88,89,90,91,27,92],"Alcohol Use Disorder (AUD)","Alcoholism","Substance Use Disorders","Cannabis Use Disorder","Methamphetamine-dependence","Cocaine Use Disorder",[94,95,96,27,92,87,97,98,99,100,101,102,103,104,105,106],"Substance Use Disorder (SUD)","Cannabise Use Disorder","Methamphetamine Use Disorder","Pavlovian-to-Instrumental Transfer (PIT)","General Pavlovian-to-Instrumental Transfer","Outcome-specific Pavlovian-to-Instrumental Transfer","Amygdala","Ventral Striatum","Neuroimaging","Humans","Surveys and Questionnaires","Reward","Cues","2024-11-19",{"date":109,"type":32},"2024-11-22",{"date":111,"type":32},"2024-08-05",{"date":113,"type":20},"2027-06-30",{"name":115,"class":39},"Technische Universität Dresden"]